These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 26700564

  • 21. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation.
    Galve-Roperh I, Chiurchiù V, Díaz-Alonso J, Bari M, Guzmán M, Maccarrone M.
    Prog Lipid Res; 2013 Oct; 52(4):633-50. PubMed ID: 24076098
    [Abstract] [Full Text] [Related]

  • 22. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M, Manning JJ, Finlay DB, Javitch JA, Banister SD, Grimsey NL, Glass M.
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [Abstract] [Full Text] [Related]

  • 23. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
    Harvey BS, Ohlsson KS, Mååg JL, Musgrave IF, Smid SD.
    Neurotoxicology; 2012 Jan; 33(1):138-46. PubMed ID: 22233683
    [Abstract] [Full Text] [Related]

  • 24. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
    Xifró X, García-Martínez JM, Del Toro D, Alberch J, Pérez-Navarro E.
    J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
    [Abstract] [Full Text] [Related]

  • 25. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C.
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [Abstract] [Full Text] [Related]

  • 26. The endocannabinoid system in Huntington's disease.
    Pazos MR, Sagredo O, Fernández-Ruiz J.
    Curr Pharm Des; 2008 Dec; 14(23):2317-25. PubMed ID: 18781982
    [Abstract] [Full Text] [Related]

  • 27. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.
    Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.
    Br J Pharmacol; 2015 Oct; 172(20):4790-805. PubMed ID: 26218440
    [Abstract] [Full Text] [Related]

  • 28. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.
    Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL.
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [Abstract] [Full Text] [Related]

  • 29. Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats.
    Silveira MM, Adams WK, Morena M, Hill MN, Winstanley CA.
    J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177
    [Abstract] [Full Text] [Related]

  • 30. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.
    Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D.
    J Neurochem; 2008 Feb; 104(4):1091-100. PubMed ID: 18028339
    [Abstract] [Full Text] [Related]

  • 31. A real time screening assay for cannabinoid CB1 receptor-mediated signaling.
    Andersen HK, Piroli GG, Walsh KB.
    J Pharmacol Toxicol Methods; 2018 Feb; 94(Pt 1):44-49. PubMed ID: 29730318
    [Abstract] [Full Text] [Related]

  • 32. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, Janero DR, Pertwee RG, Stevenson LA, Kelly ME, Denovan-Wright EM, Thakur GA.
    ACS Chem Neurosci; 2016 Jun 15; 7(6):776-98. PubMed ID: 27046127
    [Abstract] [Full Text] [Related]

  • 33. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB2 receptor.
    Bouma J, Broekhuis JD, van der Horst C, Kumar P, Ligresti A, van der Stelt M, Heitman LH.
    Biochem Pharmacol; 2023 Dec 15; 218():115924. PubMed ID: 37972874
    [Abstract] [Full Text] [Related]

  • 34. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
    Lastres-Becker I, Berrendero F, Lucas JJ, Martín-Aparicio E, Yamamoto A, Ramos JA, Fernández-Ruiz JJ.
    Brain Res; 2002 Mar 08; 929(2):236-42. PubMed ID: 11864629
    [Abstract] [Full Text] [Related]

  • 35. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview.
    Basavarajappa BS, Hungund BL.
    Prostaglandins Leukot Essent Fatty Acids; 2002 Mar 08; 66(2-3):287-99. PubMed ID: 12052043
    [Abstract] [Full Text] [Related]

  • 36. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
    Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M.
    Br J Pharmacol; 2010 Jun 08; 160(3):747-61. PubMed ID: 20590577
    [Abstract] [Full Text] [Related]

  • 37. Cannabinoid-induced autophagy regulates suppressor of cytokine signaling-3 in intestinal epithelium.
    Koay LC, Rigby RJ, Wright KL.
    Am J Physiol Gastrointest Liver Physiol; 2014 Jul 15; 307(2):G140-8. PubMed ID: 24833710
    [Abstract] [Full Text] [Related]

  • 38. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin.
    Jin YN, Yu YV, Gundemir S, Jo C, Cui M, Tieu K, Johnson GV.
    PLoS One; 2013 Jul 15; 8(3):e57932. PubMed ID: 23469253
    [Abstract] [Full Text] [Related]

  • 39. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.
    Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N.
    Eur J Neurosci; 2013 Feb 15; 37(3):429-40. PubMed ID: 23167744
    [Abstract] [Full Text] [Related]

  • 40. Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts Δ9-Tetrahydrocannabinol-Induced Cognitive Impairment.
    Aso E, Fernández-Dueñas V, López-Cano M, Taura J, Watanabe M, Ferrer I, Luján R, Ciruela F.
    Mol Neurobiol; 2019 Aug 15; 56(8):5382-5391. PubMed ID: 30610611
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.